Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma.
Hyperthermia
Immune microenvironment
Immunogenic cell death
Renal cell carcinoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
received:
30
01
2023
accepted:
23
06
2023
medline:
23
10
2023
pubmed:
13
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
In recent years, hyperthermia has been widely applied as a novel strategy for cancer treatment due to its multiple antitumour effects. In particular, the potential influences of hyperthermia on the tumour immune microenvironment may improve the efficacy of immunotherapies. However, the effect of hyperthermia on renal cell carcinoma (RCC) has not been well characterized until now. In the present study, we primarily evaluated the effects of hyperthermia on cellular function via cellular proliferation, migration, invasion and apoptosis assays. In addition, the influence of hyperthermia on the immunogenicity of RCC cells was analysed using flow cytometry analysis, enzyme-linked immunosorbent assays, and immunofluorescent (IF) staining. Our results demonstrate that hyperthermia significantly inhibits RCC cell proliferation, migration, and invasion and promotes cell apoptosis. In addition, we verified that hyperthermia improves the immunogenicity of RCC cells by inducing immunogenic cell death. Our findings suggest that hyperthermia is a promising therapeutic strategy for RCC.
Sections du résumé
BACKGROUND
BACKGROUND
In recent years, hyperthermia has been widely applied as a novel strategy for cancer treatment due to its multiple antitumour effects. In particular, the potential influences of hyperthermia on the tumour immune microenvironment may improve the efficacy of immunotherapies. However, the effect of hyperthermia on renal cell carcinoma (RCC) has not been well characterized until now.
METHODS
METHODS
In the present study, we primarily evaluated the effects of hyperthermia on cellular function via cellular proliferation, migration, invasion and apoptosis assays. In addition, the influence of hyperthermia on the immunogenicity of RCC cells was analysed using flow cytometry analysis, enzyme-linked immunosorbent assays, and immunofluorescent (IF) staining.
RESULTS
RESULTS
Our results demonstrate that hyperthermia significantly inhibits RCC cell proliferation, migration, and invasion and promotes cell apoptosis. In addition, we verified that hyperthermia improves the immunogenicity of RCC cells by inducing immunogenic cell death.
CONCLUSION
CONCLUSIONS
Our findings suggest that hyperthermia is a promising therapeutic strategy for RCC.
Identifiants
pubmed: 37828458
doi: 10.1186/s12885-023-11106-8
pii: 10.1186/s12885-023-11106-8
pmc: PMC10568811
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
972Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Trends Cancer. 2022 Jan;8(1):9-20
pubmed: 34740553
ACS Appl Mater Interfaces. 2019 Mar 27;11(12):11167-11176
pubmed: 30810026
Science. 2002 Apr 12;296(5566):301-5
pubmed: 11951032
J Immunol. 2009 Feb 1;182(3):1449-59
pubmed: 19155492
Eksp Med Morfol. 1991;30(1):51-4
pubmed: 1884689
Cancers (Basel). 2020 Feb 10;12(2):
pubmed: 32050629
BMC Infect Dis. 2017 Jan 14;17(1):74
pubmed: 28088167
Diagn Interv Imaging. 2017 Sep;98(9):651-659
pubmed: 28579522
Oncoimmunology. 2017 Mar 31;6(5):e1311433
pubmed: 28638734
Semin Nephrol. 2020 Jan;40(1):86-97
pubmed: 32130970
Curr Urol Rep. 2017 Jan;18(1):3
pubmed: 28110463
Nat Rev Cancer. 2019 Oct;19(10):568-586
pubmed: 31462760
Cancers (Basel). 2021 Nov 22;13(22):
pubmed: 34831009
Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56
pubmed: 12098606
Clin Cancer Res. 2011 Apr 15;17(8):2474-83
pubmed: 21292818
Cancers (Basel). 2021 Nov 28;13(23):
pubmed: 34885091
Acta Biomater. 2021 Oct 15;134:621-632
pubmed: 34329782
J R Soc Interface. 2021 Jul;18(180):20210266
pubmed: 34229458
Front Immunol. 2020 Nov 09;11:595207
pubmed: 33240283
Front Immunol. 2022 Aug 12;13:969447
pubmed: 36032103
Mol Cancer Ther. 2019 Dec;18(12):2433-2445
pubmed: 31527225
JAMA Surg. 2022 May 1;157(5):374-383
pubmed: 35262624
Biomolecules. 2022 Apr 29;12(5):
pubmed: 35625581
Ann Surg Oncol. 2021 Apr;28(4):2337-2345
pubmed: 32935266
Pharmacol Res. 2017 Dec;126:123-137
pubmed: 28720518
Adv Mater. 2019 Jun;31(23):e1900192
pubmed: 30916367
Cancer Biol Med. 2021 Feb 15;18(1):308-317
pubmed: 33628603